ASSET PURCHASE AGREEMENT between: STRAKAN INTERNATIONAL S.À R.L. a company organized under the laws of Luxembourg; and GTX, INC., a Delaware corporation Dated as of September 28, 2012Asset Purchase Agreement • October 3rd, 2012 • GTX Inc /De/ • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”) is entered into as of September 28, 2012 (the “Date of Agreement”), by and between GTx, Inc., a Delaware corporation (“Seller”), and Strakan International S.à r.l., a company organized under the laws of Luxembourg (“Purchaser”) (Seller and Purchaser shall hereinafter be referred to individually as a “Party,” and collectively as the “Parties”).
GTx, Inc. UNAUDITED PRO FORMA FINANCIAL INFORMATIONPro Forma Financial Information • October 3rd, 2012 • GTX Inc /De/ • Pharmaceutical preparations
On September 28, 2012, GTx, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Strakan International S.à r.l. , an affiliate of ProStrakan Group plc (the “Purchaser”), pursuant to which the Company agreed to transfer, sell and assign to the Purchaser all of the Company’s rights to the metastatic breast cancer product, FARESTON®, and certain assets related thereto (collectively, the “FARESTON® Assets”). Effective as of September 30, 2012, the Company completed the sale of the FARESTON® Assets pursuant to the Purchase Agreement for a total cash purchase price of approximately $21.67 million, including payment for purchased inventory. The Company estimates that it will realize net proceeds of approximately $19.0 million after expenses related to the sale of the FARESTON® Assets (such sale, the “Disposition”).
